Abstract:Objective To verify the efficacy and safety of intravesical instillation of Cystistat in reducing complications caused by intravesical chemotherapy after TUR-BT in non-muscle invasive bladder cancer patients. Methods One hundred and twenty patients who met the inclusion/exclusion criteria were enrolled into this multi-centered, randomized and blank controlled clinical study. Selected patients were randomized into the observation group and control group. TUR-BT was carried out in both groups followed by pirarubicin (THP) and Cystistat intravesical instillation in the observation group, and THP intravesical instillation alone in control group. Visual analog scale (VAS) was used as the primary efficacy variable. The secondary efficacy variables were assessments of hematuria and bladder irritation symptoms. Adverse events, laboratory tests and changes of vital signs before and after treatment were strictly observed during observation to evaluate the efficacy and safety of Cystistat.Results Demographics and baseline characteristics were comparable in both groups. The differences and the improvement rate of VAS score in the 2 groups were significant, both P＜0.01. The changes of VAS score and the improvement rate before and after treatment were (2. 24±1.70) and (92. 92±14.76) % in observation group and (0. 70±1.82) and (20. 59±87.34)% in control group respectively. According to the covariance analysis, there were significant differences in changes of VAS score between the observation group and the control group. Also, the improvement rate of VAS score was significant from visit 2. The urine frequency decreased from 9.06±4.09 to 6. 69±2.89 in observation group and increased from 8. 85±3. 32 to 10. 15±4.40 in control group, P＜0.01. There were also significant differences in changes of nocturia before and after treatment between these two groups (P＜0.01), the nocturia decreased from 2. 88±1.74 to 1. 47±1.62 in observation group and 3. 22±2.30 to 2.91±1.73 in control group, respectively. The changes of WHO assessment for hematuria,urgency and dysuria were not significantly different between the 2 groups. No Cystistat related adverse event was observed. Conclusions Cystistat combined instillation can significantly improve the VAS score of patients with chemotherapeutic agent instillation. Relief of bladder pain, frequency and nocturia are more rapidly and more durable in Cystistat combined instillation group. The improvement is more effective in patients with a high VAS score. Cystistat instillation with chemotherapeutics agents is both well tolerated and safe.

The Chemosensitivity Study of Superficial Bladder Cancer

Combined Modality Therapy Following Bladder Conservation Surgery for Bladder Cancers

Single-dose Instillations of Epirubicin As Prophylaxis for Recurrence of Superficial Bladder Tumors:A Prospective Randomized Controlled Study

Mitomycin Intravesical Chemotherapy for Superficial Bladder Carcinoma Guided by Histo-Culture Drug Re-Sponse Assay

The clinical investigation of different intravesical instillation of chemotherapy after transurethral resection of bladder tumors for the treatment of superficial bladder cancer

Effect of Hydroxycamptothecin Combined with Pirarubicin in the Treatment of Superficial Bladder Cancer Recurrence

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

Clinical Study of Intravesical Lifein Instillation in Prophylaxis of Postoperative Recurrence of Superficial Bladder Urothelial Carcinoma

Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer

Intravesical Instillation of Pirarubicin for Preventing Postoperative Recurrence of Superficial Bladder Cancer in 132 patients

Chemosensitivity testing of three novel bladder transitional cell carcinoma lines derived from an untreated patient and BIU-87 cell line

[Single Instillation of Epirubicin for the Prophylaxis of Recurrent Primary Superficial Bladder Carcinoma].

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

The Selection of different Endoscopic Therapy for Superficial Bladder Cancer

Chemosensitivity in vitro of 25 anti-cancer drugs to primary cultured human breast cancer cells

Complications and prevention strategies of the intravesical instillation chemotherapy drugs for bladder cancer

Investigation on the Management of Pirarubicin As the Intravesical Chemotherapy for Preventing Post-Turbt Recurrence of the Superficial Bladder Cancer

Combination of Hyperthermia and Intravesical Chemotherapy for the Treatment of Pt1 Stage Bladder Cancer: A Retrospectively Clinical Study.

Comparison of Gemcitabine and Anthracycline Antibiotics in Prevention of Superficial Bladder Cancer Recurrence

The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy

Randomized Study of Single Instillation of Epirubicin for Superficial Bladder Carcinoma: Long-Term Clinical Outcomes